Protocol Ledger

NCT04399837 · Phase II · COMPLETED

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Interventional Phase II clinical trial protocol NCT04399837 sponsored by Boehringer Ingelheim in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-04 Enrollment: 123 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04399837
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)123 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04399837
Protocol FieldVerified Registry Value
NCT IdentifierNCT04399837
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment123 participants (ACTUAL)
Registered Start Date2020-06-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI